Evidence map›Paper›PMID 36234680›Full record

ArticleMolecules (Basel, Switzerland)2022

DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway.

Mashael S Al-Mutairi, Hany O Habashy

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mashael S Al-MutairiDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Health Science Center, Kuwait University, Safat P.O. Box 5969, Kuwait.
Hany O HabashyDepartment of Histopathology and Cytology, Al-Adan Hospital, Ministry of Health, Kuwait, and Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0003-3685-5273
Kuwait University · KWMansoura University · EG

Funding

Health Science Center RCF SRUL02/13Kuwait University NM01/14
6 · The paper itself

Abstract

Doxorubicin (Dox) has limited efficiency in breast cancer (BC) due to drug-acquired resistance. The epithelial-mesenchymal transition (EMT) plays a major role in the survival and drug resistance of cancer cells. It was suggested that the JNK pathway was implicated in the response to Dox by regulating EMT. DUSP4/or MKP-2 is a well-known regulator of the JNK pathway and was found to be highly expressed in BC. However, its functional significance is not yet fully understood. In the present study, the possible involvement of MKP-2 in Dox-induced EMT was investigated in breast cancer cells. Immunohistochemistry for tissues obtained from BC patients (

Indexed as

Breast NeoplasmsAdultApoptosisCell Line, TumorDoxorubicinDrug Resistance, NeoplasmDual-Specificity PhosphatasesEpithelial-Mesenchymal TransitionFemaleHumansKi-67 AntigenMAP Kinase Signaling SystemMitogen-Activated Protein Kinase PhosphatasesDoxorubicinDual-Specificity PhosphatasesDUSP4 protein, humanKi-67 AntigenMitogen-Activated Protein Kinase Phosphatasesbreast cancerchemoresistancedoxorubicinDUSP4EMTJNK

Identifiers

PMID36234680
PMCPMC9572343
OpenAlexW4296742164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.